Who was studied
Children and adolescents 5 to 18 years of age with CF, currently taking pancreatic enzyme replacement therapy (PERT), and with mild to moderate lung disease were recruited from 10 CF centers.
How they were studied
For 1 year:
What the study measured
Encala’s effectiveness was measured by improvement in overall fat absorption, weight, height, and BMI increases.